Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new potential strategy for boosting the immune system’s ability to fight cancer. Studies in gene knockout mice, carried out in collaboration with a team at NYU Langone’s Perlmutter Cancer Center, suggested that a protein known as Siah2 is involved in the control of T
Scientists at UCL have identified how a subset of immune cells are activated to kill cancerous cells, a finding in mice which could hold the key to new powerful therapies against cancer. This new study built on previous research*, also led by Professors Sergio Quezada and Karl Peggs (both UCL Cancer Institute), which found that
Source Targeted Oncology The clinical development and application of cancer immunotherapy over the past decade has translated the long-standing knowledge of the close relationship between cancerous tissues and lymphoid immune cells, dating back to the late 19th century.1,2 Today, cancer immunotherapies, all of which recruit the body’s own immune system to target and eliminate cancer cells,
Researchers have found a new way to use math to better treat cancer and prevent its relapse. Using the first mathematical model of its kind, researchers at the University of Waterloo found a way to study the interactions between the immune system and different types of cancer cells. Using their new model, the researchers found
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has received Orphan Designations from the European Commission (EC) for paclitaxel and encequidar (“Oral Paclitaxel”) for the treatment of soft tissue sarcoma, following a positive opinion from the
Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell
The European Commission (EC) has approved a combination regimen of Bavencio (avelumab) injections plus Inlyta (axitinib) tablets for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The combination can be used in patients regardless of their predicted prognosis and PD-L1 status. The EC’s decision followed a positive recommendation issued in September by the Committee for Medicinal
Combination therapy with BRAF and MEK inhibitors conferred significant PFS benefit compared with BRAF inhibitor monotherapy among patients with metastatic melanoma with rare BRAF mutations or translocations, according to results of an international, retrospective study published in Journal of Clinical Oncology. “Patients with rare BRAF mutations may respond to targeted therapy, however, efficacy seems to be lower compared with patients
The immune system is very effective against invading pathogens such as viruses and bacteria, as well as cancer cells that arise through genetic mutation. The activity of the immune system must be kept in check, however, to maintain homeostasis and avoid the development of autoimmune conditions. The immunosuppressive mechanisms that accomplish this can be co-opted
The year 2019 has offered up many advances in immunotherapy. These advances shed light on such important aspects as biomarkers, better targeted therapies, chemotherapy outcomes, and resistance. Summarized herein are several high-profile conference presentations that highlight key advances in the field. The year has not quite come to an end yet, but as predicted by
